Τόμος 10 (1996) – Τεύχος 1 – Άρθρο 3 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 10 (1996) – Issue 1 – Article 3 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

By | | Α. Καζής - A. Kazis, Κ.Β. Καπινάς - K.B. Kapinas, Κλινική Μελέτη - Clinical Trial, Μαγδαληνή Ν. Τσολάκη - M.N. Tsolaki, Πλήρες Κείμενο στα Αγγλικά - Full Text in English
Title Nimodipine vs dihydroergocristine in the treatment of old age dementias: a blind, randomized, placebo-controlled study
Authors M. Tsolaki, K. Kapinas and A. Kazis

3rd Department of Neurology, Aristotle University of Thessaloniki, General Hospital G. Papanicolaou, Exohi, Thessaloniki, Macedonia, Greece
Citation Tsolaki, M., Kapinas, K., Kazis, A.: Nimodipine vs dihydroergocristine in the treatment of old age dementias: a blind, randomized, placebo-controlled study, Epitheorese Klin. Farmakol. Farmakokinet. 10(1): 16-24 (1996)
Publication Date Received for publication: 1996

Accepted for publication: 1996
Full Text Language English
Order – Buy  pharmakonpress[at]pharmakonpress[.]gr
Keywords Nimodipine, dihydroergocristine, dementias, AAMI, therapy.
Other Terms Clinical Trial
Summary In a placebo-controlled, double blind, randomized clinical study in 99 elderly patients with cognitive decline, nimodipine and dihydroegocristine were found to be therapeutically effective agents in the treatment of old age dementias. DSM-IIIR and NINCD-ADRDA criteria were used for the diagnosis of Alzheimer’s Disease. DSM-IIIR criteria were used for the diagnosis of vascular dementia. Hachinski score and CT scan were used for the differential diagnosis between Alzheimer’s Disease and Vascular dementia. MMSE, CAMCOG and FRSSD were used in the assessment before and after treatment. GDS and Hamilton scales were used to exclude patients with depression. CT scan was performed in all patients. Treatment with 45-90 mg of nimodipine administered orally in divided doses, and 6 mg of dihydroergocristine for three months in 33 patients with Alzheimer’s Disease, in 31 patients with vascular dementia and 35 patients with Age Associated Memory Impairment. Placebo was administered in the same patients for the same duration before treatment with nimodipine or dihydroergocristine. Wilcoxon matched pairs test was used for statistical analysis. Both agents prevented further significant decline in patients with Alzheimer Disease and were significant superior to an inactive placebo. Both agents improved significantly patients with Age Associated Memory impairment and Vascular dementia.
References 1.     Branconnier R.J., Branconnier M.E., Walshe T.M., McCarthy C., Morse P.A.: Blocking the Ca2+-0-activated cytotoxic mechanisms of cholinergic neuronal death: a novel treatment strategy for Alzheimer’s disease. Psychopharmacol. Bull. 28: 175-181 (1992)2.     Frackowiak R.S.J., Pozzilli C., Legg N.J., DuBoulay G.H., Marrshall J., Lenzi G.L., Jones T.: Regional cerebral oxygen supply and utilization in dementia. Brain 194: 753-778 (1981)3.     Tollefson G.D.: Short term effects on the calcium channel blocker nimodipine in the management of primary degenerative dementia. Biol. Psychiatry 27: 1133-1142 (1990)

4.     Snyder S.H., Reynolds I.J.: Calcium-antagonist drugs. Receptor interactions that clarify therapeutic effects. N. Engl. J. Med 313: 995-1002 (1985)

5.     Reichle M.E.: The pathophysiology of brain ischaemia. Ann. Neurol. 13: 2-10 (1983)

6.     Yamomoto M., Ohta T., Toda N.: Mechanisms of relaxant action of nicardipine, a new Ca++ antagonist, on isolated dog cerebral and mesenteric arteries. Stroke 14: 270-275 (1983)

7.     Grotta J.C.: Current medical and surgical therapy for cerebrovascular disease. N. Engl. J. Med. 377: 1506-1517 (1987)

8.     Ban T.A., Morey L., Aguglia E., Azzareili O., Balsano F., Marigliano V., Caglieris N., Sterlicchio M., Capurso A., Tomasi N.A. et al.: Nimodipine in the treatment of old age dementias. Prog. Neuropsychopharmacol. Biol. Psychiatry 14: 525-551 (1990)

9.     Centonze V., Massaro C., Polito B.M., Cassiano M.A., Di Bari M., Russo P., Cirillo L., Albano O.: Brain aging and calcium antagonist drugs. A preliminary open study with nimodipine. Clin. Ter. 140: 11-15 (1992)

10.    Steen P.A., Newberg I.A., Milde J.H., Michenfeider J.D.: Nimodipine improves cerebral blood flow and neurologic recovery after complete cerebral ischaemia in the dog. J. Cereb. Blood Flow Metab. 3: 38-43 (1983)

11.    Wahlgren N.G.: Acute stroke therapy – Calcium blockers. 2nd International Conference on Stroke, Geneva, Switzerland 1993

12.    Goldstein M., Lew J.Y., Hata F., Lieberman A.: Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology (Suppl 1): 24:76 (1978)

13.    Suchy I.H.: Clinical effects of dopamine agonists in elderly patients. In: Lisuride and other Dopamine Agonists (D.B. Caine et al., eds), p. 529, Raven Press, New York

14.    Lucchelli A., Zonta F., Grana E., Turba C., Pagella P.: Dualism in the alpha-adrenoreceptor blocking action of dihydroergocristine. Pharmacol. Res. Comm. 13: 23 (1981)

15.    Morpurgo C., Faini D., Falcone A.: Effects of phentolamine, dihydroergocristine and isoxuprine on the blood pressure and heart rate in normotensive, hypotensive and hypertensive rats. Naunyn. Schmiedeberg’s Arch. Pharmacol. 290: 335 (1975)

16.    Grana E., D’ Agostino G., Zonta F., Lucchelli A.: Actions and interactions of ergotamine and dihydroergocristine in rat aortic strips. Farmaco, Ed. Sei. 8: 109 (1981)

17.    D’ Urso R., Falaschi P., Jeccamo R., Ruggieri S.: Effect of dihydroergocristine on prolactin release from isolated and dispersed rat pituitary cells. Acta Ther. 8: 109 (1982)

18.    Poli M., Bonetti M., Bosi E.: Effeto inhibitorio della diidroergicristina sulla secrezione di prolattina indotta da sulpiride e da cimetidina nell’ uomo. J. Endocrinol. Invest. 3 (Suppl 1): 32 (1980)

19.    Gamba G., Grignani G., Dolci D.: Effeto in vivo della diidroergocristina sulla funzione di piastrine umane. Arch. Set. Med. 135: 249 (1978)

20.    Benzi G., Arrigoni E., Pastoris O., Raimondo S., Dossena M., Fulle D., Tumminello M.C., Villa R.F.: Drug interference on some biochemical parameters of rat cerebral cortex during post-ischemic recovery. Arch. Int. Pharmacodyn. Ther. 247: 198 (1980)

21.    Venutti P., Ferretti C., Portaleone P.: Ergot alkaloids and phosphodiesterase in vitro activities, in several rat brain areas. Experientia 38: 601 (1982)

22.    Kohlmeyer K., Blessing J.: Zur Wirkung von Dihydroergocristine-methansulfonat auf den Hirnkreislauf des Menschen in Akutversuch. Unteruchungen mit der intrakaritidialen 133Xenon-clearance-Method. Arzneim.- Forsch. 28: 1788 (1978)

23.    Agnoli A., Manna V., Bocola V., Martucci N.: Chronic cerebro-vascular disorders: Modifications of the EEG spectral analysis determined by dihydroergocristine methanesulfonate. Curr. Ther. Res. 20: 321 (1981)

24.    Martucci N., Manna V., Prencipe M., Agnoli A.: Validation of pharmaco-EEG and neuropsychology as experimental methods in clinical neuropharmacology. In: Cerebral pathology in Old Age. Neuroradiological and Neurophysiological Correlations (A. Cecchni et al., eds), p. 373, EMI RAS, Pavia, 1983

25.    American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition revised, pp. 97-134, DSM IHR, 1987

26.    Report of the NINCDS-ADRDA Work Group: Clinical diagnosis of Alzheimer’s disease. Neurology 34: 939- 944 (1984)

27.    Folstein M.F., Folstein S.E., McHugh P.R.: MMSE: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189-198 (1975)

28.    Fountoulakis K., Tsolaki M., Chantzi E., Kazis A.: Mini Mental State Examination. Validation Study in Demented Patients from the elderly Greek Population. 9th Greek Conference for Neurosciences, Book of Abstract 36, Thessaloniki, 1993

29.    Roth M., Huppert F.A., Tym E., Mountjoy C.Q.: CAMDEX. Cambridge University Press, 1988

30.    Hachinski V.V., Iliff L.D., Zihkla E et al.: Cerebral blood flow in dementia. Arch. Neurol. 32: 632-637 (1975)

31.    Hutton J.T.: Alzheimer’s Disease. In: Conn’s Current Therapy. 778-781 (1990)

32.    Hamilton M.: A Rating Scale for depression. J. Neurol. Neurosurg. Psychlatr.: 23-56 (1960)

33.    Sheikh J.I., Yesavage J.A.: Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin. Gerontologist 5: 165-173 (1986)

34.    Crook T.H., Bartus R.T., Ferris S.H., Whitehouse P., Cohen G.D., Gershon S.: Age associated memory impairment: proposed diagnostic criteria and measures of clinical change. Report of the National Institute of Mental Health Workgroup. Develop. Neuropsychol. 2: 261-276 (1986)

35.    Sclar D.A., Skaer T.L.: Current concepts in the treatment of Alzheimer’s disease. Clin. Ther. 14: 2-10 (1992)

36.    Cooper J.K.: Drug treatment of Alzheimer’s disease. Arch. Int. Med. 151: 245-249 (1991)

37.    Tedeschi D.: Calcium regulation in brain aging by nimodipine: a multicenter trial in Italy. Curr. Ther. Res. 50: 553-563 (1991)

38.    Ulrich G., Stieglitz R.D.: Effect of nimodipine upon EEG Vigilance in elderly persons with minor impairment of brain functions. Arzneim. -Forsch. 3: 392-396 (1988)

39.    Ban T.A., Morey L., Aguglia E., et al.: Nimodipine in the treatment of old age dementias. Prog. Neuropsychopharmacol. Biol. Psychiatry 74: 525-551 (1990)

40.    Tollefson G.D.: Short term effects of the calcium channel blocker nimodipine in the management of primary degenerative dementia. Biol. Psychiatry 27: 1133-1142 (1990)

41.    Weiss J.H., Pike C.J., Cotman C.W.: Ca2+ channel blockers attenuate beta-amyloid peptide toxicity to cortical neurons in culture. J. Neurochem. 62: 372-375 (1994)

42.    Branconnier R.J., Branconnier M.E., Walshe T.M., McCarthy C.: Blocking the Ca2+-activated cytotoxic mechanisms of cholinergic neuronal death. Psychopharmacol. Bull. 28: 175-181 (1992)

43.    Hulla F.W.: Presentation of data from European nimodipine studies. Sixth Congress of the International Psychogeriatric Association, Berlin, 1993

44.    Schmage N., Bergener M.: Global rating, symptoms, behavior and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes. Int. Psychogeriatr. Suppl 1: 89-99 (1992)

45.    Reimann I.: Alzheimer’s disease. Starting points in drug therapy. Dtsch. Apoth. Ztg.: 959-969 (1990)

46.    Jann M.W., Miller S.W., Miyahara R., et al.: A controlled clinical trial of nimodipine in the treatment of patients with Primary Degenerative Dementia (PDD). Pharmacotherapy 12: 507 (1992)

47.    Branconnier R.J., Harto N.E., Dessain E.C., Cole J.O.: Palliation of the progressive memory impairment of Alzheimer’s disease by nimodipine. Psychopharmacology 96 (Suppl.): 242 (1988)

48.    Dessain E.C., McNiff M.E., Spera K.F., Branconnier RJ.: Nimodipine induced normalization of the EEG in Primary Degenerative Dementia. Acta Pharmacol. Toxicol. 59 (Suppl, 5): 104 (1986)

49.    Grobe-Einsler R.: Clinical aspects of nimodipine, Clin. Neuropharmacol. 16 (Suppl. 1): S39-S45 (1993)

50.    Hilgert D., Eicher H., Liebl D., et al.: Nimodipine therapy of multimorbid geriatric patients with organic psychosyndrome: Pharmacodynamics and Pharmacokinetics. Med. Welt 43(1): 20-26 (1992)

51.    Imperato A., Obinu M.C., Dazzi L, Carata G., Mascia M.S., Casu M.A., Gessa G.L.: Co-dergocrine (Hydergine) regulates striatal and hippocampal acetylcholine release through D2 receptors. Neuroreport 5: 674-676 (1994)

52.    Favit A., Sortino M.A., Aleppo G., Scapagnini U., Canonico P.L.: Protection by dihydroergocryptine of glutamate-induced neurotoxicity. Pharmacol. Toxicol. 73: 224-228 (1993)

53.    Abate G., Angelert F., Bartorelli L, Batistin L, Bergamasco B., Bertolini S., Bulfoni A., Capurso A., Cazzato G., Covvagna G., et al.: Epidemiologic study on the effectiveness and safety of dihydroergocrystine in impaired memory and behavioral functions in aged humans. Arzneim.-Forschung 42: 1417-1421 (1992)

54.  Agliati G., Lazzaroni M., Mariani G., Marras F., Masseto N., Menozzi C., Ortenzi E., Perna G., Puppo N., Santambrogio S., et al.: One year therapy with dihydergocrystine for treatment of impaired alertness and memory in elderly patients. Placebo-controlled multicenter study. Arzneim.-Forschung 42: 1414-1416 (1992)
Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Συντακτικη Επιτροπή-Editorial Board

 

 

 

Bookmark the permalink.

Comments are closed.